Lenvatinib Mesylate Intermediate CAS 205448-65-3 Maʻemaʻe >98.0% (HPLC) Hale Hana
ʻO Ruifu Chemical Supply Lenvatinib Mesylate Intermediates Me ka Maʻemaʻe Kiʻekiʻe
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Inoa Kimia | Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate |
Nā huaʻōlelo like | 1,4-Dihydro-7-Methoxy-4-Oxo-6-Quinolinecarboxylic Acid Methyl Ester;7-Methoxy-4-Oxo-1,4-Dihydro-Quinoline-6-Carboxylic Acid Methyl Ester;Lenvatinib Intermediate 3 |
Helu CAS | 205448-65-3 |
Helu CAT | RF-PI1973 |
Kūlana Kūʻai | Ma ka waihona, ka mana hana 50 MT / Makahiki |
ʻĀpana Molekala | C12H11NO4 |
Kaumaha Molecular | 233.22 |
Lae paila | 421.0±45.0℃ |
ʻO ka mānoanoa | 1.267±0.060 g/cm3 |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pau-Keʻokeʻo a Melemele |
Maʻemaʻe / Kaʻina Hanana | >98.0% (HPLC) |
Nalo ma ka maloo | <1.00% |
Koena ma ka Ignition | <0.50% |
Huina paumaele | <2.00% |
H-NMR | Kūlike i ka hoʻolālā |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Nā Kūwaena Lapaʻau |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;E pale i ka malamalama a me ka wai
ʻO Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate (CAS: 205448-65-3) kahi mea waena o Lenvatinib Mesylate (CAS: 857890-39-2).ʻO Lenvatinib, i kūʻai ʻia ma lalo o ka inoa inoa ʻo Lenvima ma waena o nā mea ʻē aʻe, he lāʻau anti-cancer no ka mālama ʻana i kekahi ʻano maʻi maʻi thyroid a no nā maʻi maʻi ʻē aʻe pū kekahi.Ua hoʻomohala ʻia e Eisai Co. a hana ma ke ʻano he mea hoʻopaneʻe kinase lehulehu e kūʻē i nā kinase VEGFR1, VEGFR2 a me VEGFR3.Ua ʻae ʻia ʻo Lenvatinib (mai ka makahiki 2015) no ka mālama ʻana i ka maʻi maʻi thyroid ʻokoʻa i ʻike hou ʻia a i ʻole metastatic, holomua, a ʻaʻole i pane i ka mālama ʻana me ka iodine radioactive (radioiodine).Ma Mei 2016, ua ʻae ka US Food and Drug Administration (FDA) iā ia (i hui pū me everolimus) no ka mālama ʻana i ka maʻi maʻi maʻi maʻi renal cell ma hope o hoʻokahi lāʻau anti-angiogenic mua.Ua ʻae ʻia ka lāʻau lapaʻau i ka US a me ka European Union no ka maʻi hepatocellular carcinoma ʻaʻole hiki ke hoʻoneʻe ʻia i nā mea maʻi i loaʻa ʻole i ka maʻi maʻi maʻi ma ka waha a i ʻole ka injection.